Suppr超能文献

在营养补充剂中鉴定生长激素释放肽-2(GHRP-2)。

Identification of the growth-hormone-releasing peptide-2 (GHRP-2) in a nutritional supplement.

机构信息

Center for Preventive Doping Research/Institute of Biochemistry, German Sport University Cologne, Germany.

出版信息

Drug Test Anal. 2010 Mar;2(3):144-8. doi: 10.1002/dta.120.

Abstract

Black market products of a pharmaceutical nature and nutritional supplements have received substantial and increasing attention because of potential performance enhancement in elite and non-professional sports. In addition, improved general health is claimed for non-competing individuals. The risks and foreseeable dangers of the uncontrolled use of highly potent and non-approved pharmaceutical compounds in healthy individuals are of considerable concern. In the present case report, the emerging drug candidate GHRP-2 with verified growth-hormone-releasing properties was identified and quantified in tablets offered as an over-the-counter nutritional supplement. The impact of this orally active peptide on the hGH/IGF-axis has been established for several years and its illicit use in elite sports has been assumed. As a releasing factor for hGH, GHRP-2 belongs to the list of substances prohibited by the World Anti-Doping Agency (WADA). Unfortunately, to date there is no routinely performed assay for the determination of these peptides potentially occurring in biological fluids of competing athletes, but the present data will facilitate the implementation by providing principle analytical information on liquid chromatographic and mass spectrometric behaviour. Qualitative identification of the target analyte after extraction from the tablet matrix was performed by high resolution/high accuracy mass spectrometry after liquid chromatographic separation under consideration of the accurate masses and the ratios of the protonated molecules and their fragment ions derived from their collisionally induced dissociation. Quantitative results were obtained by means of liquid chromatography coupled to a triple quadrupole mass spectrometer and linear regression using an external calibration curve (with GHRP-2 reference compound) adjusted via internal standard (Hexarelin). Hereby, the content of GHRP-2 was determined with approximately 50 µg per tablet.

摘要

由于在精英和非职业运动中具有潜在的性能提升作用,具有药物性质的黑市产品和营养补充剂受到了极大的关注。此外,非参赛个体声称可以提高整体健康水平。在健康个体中不受控制地使用高浓度和未经批准的药物化合物的风险和可预见的危险引起了相当大的关注。在本案例报告中,已鉴定和定量出作为非处方营养补充剂提供的片剂中具有经证实的生长激素释放特性的新兴药物候选物 GHRP-2。 该口服活性肽对 hGH/IGF-轴的影响已确立多年,并且假设其在精英运动中的非法使用。作为 hGH 的释放因子,GHRP-2 属于世界反兴奋剂机构(WADA)禁止的物质清单。不幸的是,迄今为止,尚无常规方法可用于测定可能存在于竞争运动员生物体液中的这些肽,但目前的数据将提供有关液质联用行为的分析信息,从而有助于实施。 通过考虑准确质量以及源自其碰撞诱导解离的质子化分子及其碎片离子的比例,从片剂基质中提取目标分析物后,通过高分辨率/高精度质谱法进行定性鉴定。通过液相色谱-三重四极杆质谱联用和使用外部校准曲线(使用 GHRP-2 参考化合物)并通过内标(Hexarelin)进行调整的线性回归,获得定量结果。 由此,每片确定 GHRP-2 的含量约为 50μg。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验